[HTML] frontiersin.org

[HTML][HTML] Real-world efficacy and safety of anlotinib with and without immunotherapy in advanced non-small cell lung cancer

Q Xiong, B Qin, L Xin, B Yang, Q Song, Y Wang… - Frontiers in …, 2021 - frontiersin.org
Aims Combination of anti-angiogenesis therapy and immunotherapy has showed synergistic
effects in non-small cell lung cancer (NSCLC). The aim of this retrospective study was to …
被引用次数：24 相关文章

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer.

Q Xiong, B Qin, L Xin, B Yang, Q Song, Y Wang… - Frontiers in …, 2021 - europepmc.org
Aims Combination of anti-angiogenesis therapy and immunotherapy has showed synergistic
effects in non-small cell lung cancer (NSCLC). The aim of this retrospective study was to …
[HTML] nih.gov

[HTML][HTML] Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer

Q Xiong, B Qin, L Xin, B Yang, Q Song… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Aims Combination of anti-angiogenesis therapy and immunotherapy has showed synergistic
effects in non-small cell lung cancer (NSCLC). The aim of this retrospective study was to …

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer

Q Xiong, B Qin, L Xin, B Yang, Q Song… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Aims Combination of anti-angiogenesis therapy and immunotherapy has showed synergistic
effects in non-small cell lung cancer (NSCLC). The aim of this retrospective study was to …